louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03258307: Comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone Levels Pre-post Omentectomy
Official title: Comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone Levels Derivated From Adipose Tissue Pre-postoperatively in Patient Diagnosed With Gynecological Malignancy Performed Omentectomy or Not
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gynecologic Cancer
Lead sponsor: Istanbul Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2017-08-23
Enrollment: 25
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Omentum is adipose tissue lying under inner anterior wall Omentectomy is routine procedure in treatment of gynecological malignancy especially ovarian cancer and some advanced stage endometrial cancer. Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone secrete from adipose tissue. These regulate matabolic process.

We aimed comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone levels derivated from adipose tissue pre-postoperatively in patient diagnosed with gynecological malignancy performed omentectomy or not

Detailed description: Omentum is adipose tissue lying under inner anterior wall Omentectomy is routine procedure in treatment of gynecological malignancy especially ovarian cancer and some advanced stage endometrial cancer. Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone secrete from adipose tissue. These regulate matabolic process.

We aimed comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone levels derivated from adipose tissue pre-postoperatively in patient diagnosed with gynecological malignancy performed omentectomy or not. Blood sample will study after 4000 rpm centrifugal for 10 minutes

Eligibility criteria: Inclusion Criteria:

* gynecologic malignancy, staging surgery with or without omentectomy

Exclusion Criteria:

* not accept inclusion to trial

Primary outcomes:
measure: with omentectomy group
timeFrame: 1 year
measure: No omentectomy group
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Bakirkoy Dr Sadi Konuk Training and Research Hospital
Study officials:
References:
citation: Comba C, Ozdemir IA, Demirayak G, Erdogan SV, Demir O, Ozlem Yildiz G, Bulut H, Karakas S, Gulseren V, Afsar S, Gungorduk K. The effect of omentectomy on the blood levels of adipokines in obese patients with endometrial cancer. Obes Res Clin Pract. 2022 May-Jun;16(3):242-248. doi: 10.1016/j.orcp.2022.06.002. Epub 2022 Jun 11.
Clinical trial NCT02976207: Long Follow up on Patients With Obstructive Sleep Apnea That Undergo Diagnosis and Surgical Treatment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: OSA
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2016-11-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.

Brief summary: Long follow up on patients with obstructive sleep apnea that undergo diagnosis and surgical treatment

Detailed description: Drug induced sleep endoscopy (DISE) is increasingly performed procedure, offering dynamic upper airway evaluation during artificial sleep before surgical treatment for patients with obstructed

.)OSA(sleep apnea

* Aim: To evaluate the value of DISE for tailoring the proper treatment for patients with snoring and OSA DISE is a safe procedure, easily practicable, valid and reliable. We consider it a fundamental clinical procedure that is essential before choosing the surgical treatment. Our results so far suggest that a multilevel collapse is significantly associated with higher apnea hypopnea index values. We think that the weight did not play a significant role in RDI (Respiratory Disturbance Index) reduction. Our results till now show tailored surgery based on DISE may leverage sleep surgeries outcome significantly presenting 70% success rate based
* on our experience We therefore want to evaluate the patients in a long follow up period

Eligibility criteria: Inclusion Criteria:

* Fully diagnosed patients with OSA.
* Patients who are candidates for a surgery as a treatment to their condition.

Exclusion Criteria:

* Pregnancy
* Patients who are not OSA surgery candidates.
* Patients with high surgical risk.
* Patients with hematological or oncological background.

Primary outcomes:
measure: Measurement of daytime sleepiness- using Epworth sleepiness scale questionnaire
timeFrame: up to 3 years after surgery
measure: Sleep quality assessment questionnaire
timeFrame: up to 3 years after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yafe medical center
Study officials:
References:
Clinical trial NCT06682507: High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)
Official title: High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lupus Nephritis (LN)
Keywords: lupus
lupus nephritis
outcomes
end stage kidney disease
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2024-11-12
Enrollment: 5000
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who had biopsy proven lupus nephritis in The First Affiliated Hospital of Sun Yat-sen University

Brief summary: The goal of this observational study is to learn about the long-term renal and patient's survival of lupus nephritis (LN) patients in China. The main question it aims to answer is:

Does the renal and patient's survival improved in the long term period? Participants who had renal biopsy proven lupus nephritis in one hospital will be followed up.

Detailed description: Patients from 1996-2016 were retrospective enrolled and patients starting from 2017 were prespective enrolled

Eligibility criteria: Inclusion Criteria:

Patients who had biopsy proven lupus nephritis in The First Affiliated Hospital of Sun Yat-sen University

Exclusion Criteria:

* less than 14 years old
* refused to give written consent

Primary outcomes:
measure: Rate of patients with end stage renal disease
timeFrame: From data of enrollment until the data of first documented end stage renal disease, assessed up to 50 years
Secondary outcomes:
measure: Rate of patient's mortality
timeFrame: From data of enrollment until the data of death, assessed up to 50 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Wei Chen, MD PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00018707: Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress
Official title: Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gulf War Syndrome
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-07-05
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: This is the follow-up to an observational epidemiological study of psychological and neuropsychological outcomes of deployed and non-deployed Gulf War-era veterans.

Detailed description: Approximately 800 deployed and 250 nondeployed veterans were originally administered psychological assessment instruments shortly after the cessation of the Gulf War. These veterans are currently being followed to evaluate longer-term psychological outcomes in relation to war-zone stress, intervening life stress, and individual difference factors and personal resources, such as coping and social support.

Approximately 75 of these veterans, oversampled for post-traumatic stress disorder, were administered a specialized neuropsychological battery emphasizing attention and memory. This sample will also be followed to evaluate longitudinal neuropsychological outcome in relation to PTSD status.

A cross-sectional study will also be conducted examining visual, hierarchical attention in relation to PTSD diagnosis.

Eligibility criteria: Participation in Time 1 data collection

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: VA, New Orleans
state: Louisiana
Study officials:
References:
Clinical trial NCT00445107: SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
Official title: An Open Label, Observational Study to Assess The Efficacy, Safety and Tolerability of Added Singulair in Persistent Asthma Patients With or Without Allergic Rhinitis and Long Acting B-Agonist
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2007-03-08
Enrollment: 198
Sex: ALL
Minimum age (years): 15
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.


Eligibility criteria: Inclusion Criteria:

* Patient is currently a nonsmoker and has been a nonsmoker for at least 1 year
* Patient with clinical evidence of mild/moderate asthma with or without allergic rhinitis

Exclusion Criteria:

* Patient has been treated in an emergency room for asthma within 4 weeks or has been hospitalized for asthma within 3 months prior to visit 1
* Patient with severe asthma, upper respiratory infection, sinusitis, infectious rhinitis, non-allergic rhinitis
* Patient has any active, acute, or chronic pulmonary disorder that is documented by history, physical examination

Primary outcomes:
measure: Change of the asthma control questionnaire scores taken over 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04128709: Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use
Official title: Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Urinary Bladder, Neurogenic
Keywords: urodynamics
neurogenic
bladder
Lead sponsor: University of Iowa
Sponsor class: OTHER
First posted: 2019-10-16
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The investigators have developed a novel pressure monitoring device that hooks to standard urinary catheters that are used by patients with a neurogenic bladder on daily clean intermittent catheterization. The device has already been demonstrated to be accurate compared to the gold standard in clinic urodynamics. This study will assess the patients and care givers ability and experience using the device in a home setting.

Detailed description: For patients with neurogenic bladder, regular monitoring of bladder pressure and capacity is a critical component of maintaining renal and urinary health. This monitoring is currently done by in-office urodynamics testing (UDS). This testing is done intermittently, leaving open the possibility of worsening of bladder function and renal deterioration between testing sessions.

This study utilizes a novel pressure monitoring device which is portable and attaches to the end of a standard urinary catheter. The investigators will be investigating if this device can be used by patients or their caregivers in a home setting.

This study will enroll patients with neurogenic bladder that currently perform clean intermittent catheterization on a daily basis as part of their regular care. The patients will be asked to use the device at least twice a day for two weeks.

Eligibility criteria: Inclusion Criteria:

* must have diagnosed neurogenic bladder

Exclusion Criteria:

* None

Primary outcomes:
measure: Home use of bladder pressure monitoring device
timeFrame: Two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa Hospital and Clinics
state: Iowa
Study officials:
affiliation: University of Iowa
name: Christopher S Cooper, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02516709: Linear Source Registry for Prostate Cancer
Official title: CivaString Registry for Prostate Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Lead sponsor: CivaTech Oncology
Sponsor class: INDUSTRY
First posted: 2015-08-06
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients currently indicated for brachytherapy, implanted with the linear LDR source for prostate cancer with a life expectancy greater than 5 years

Brief summary: Ongoing follow up for subjects implanted with the Linear Source String for prostate cancer.

Detailed description: This registry is being conducted to provide long term analysis on the use of the linear Civastring source for prostate cancer. Prospective data collection will record and demonstrate biochemical response rates. Long term side effects and adverse events will be monitored.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old
* Plans to remain in care of enrolling physician for 5 years
* \> 5 years life expectancy
* Signed informed consent
* Enrolled within 6 weeks of implant or within 365 days of prior implant

Exclusion Criteria:

* Not willing or able to comply with protocol visit schedule

Primary outcomes:
measure: Biochemical Response Rate (PSA)
timeFrame: Up to 5 years
Secondary outcomes:
measure: Side Effects (IPSS, IIEF, RFAS score)
timeFrame: Up to 5 years
measure: Adverse Events
timeFrame: Up to 5 years
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Chicago Prostate Cancer Center
state: Illinois
city: New York
country: United States
facility: Manhattan Medical Researcch
state: New York
city: Norfolk
country: United States
facility: Bon Secours DePaul Medical Center
state: Virginia
Study officials:
affiliation: CivaTech Oncology
name: Kristy Perez, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03573609: Evaluation of the Effectiveness and Safety of Supratube Device
Official title: Multicenter, Controlled, Randomized Clinical Trial to Evaluate the Effectiveness and Safety of the New Supratube Invention Device to Prevent Pneumonia Associated With Mechanical Ventilation: " Supra-nav Project "
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intensive Critical Unit
Pneumonia
Aspiration
Prevention and Control
Lead sponsor: Fundación Cardiovascular de Colombia
Sponsor class: OTHER
First posted: 2018-06-29
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Purpose of the trial:

Trial design: Two-parallel arm, double-blind, individually randomized controlled trial.

Primary endpoint:

Clinical evaluation of sinus, oropharyngeal, tracheal, bronchial or pulmonary infections during orotracheal intubation and hospital admission.

Secondary endpoints:

Volume of oropharyngeal secretions aspirated per unit of time (for 24 hours) by the SupraTube and Complications during the use of the SupraTube device: erosions, lacerations, Bleeding, displacement, migration, need for withdrawal.

Inclusion criteria:

* Adult patient
* Orotracheal intubation ≤ 72 hours
* Hospitalized in ICU
* integrity of upper airways

Exclusion criteria:

* International patients
* Coagulopathic patients
* oncology patients
* patients with maxillofacial surgery
* Absence of close responsible family member
* Tracheostomy, shock, local or systemic non-controlled infection

Trial treatment:

Intervention:

Aspiration of secretions with the supranav device

Control:

Usual respiratory care

Expected sample size, enrollment and expected number of centers:

Sample size = 108

Recruitment start date:

Recruitment end date:

Follow-up end date:

Number of centers: 2

Statistical considerations:

* Intention to treat analysis
* The primary outcomes will be analyzed using


Eligibility criteria: Inclusion Criteria:

* Intubated adult patients with mechanical ventilation.
* To have a closest responsible relative
* Integrity of the airways

Exclusion Criteria:

* Need of orofacial, cervical or respiratory tract surgical procedures
* Patients with tracheostomy
* Shock,
* Local or systemic uncontrolled infection
* Blood dyscrasia, neoplastic diseases
* Physiological alteration
* Acute or chronic decompensated pathology that is not controlled at the time of selection.

Primary outcomes:
measure: Ventilator associated events
timeFrame: 24 hours after extubation
Secondary outcomes:
measure: Adverse events
timeFrame: 24 hours after extubation
Other outcomes:
Locations:
city: Piedecuesta
country: Colombia
facility: Fundación Cardiovascular de Colombia
state: Santander
Study officials:
affiliation: Fundación Cardiovascular de Colombia
name: Alba L Ramirez Sarmiento, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01081509: Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
Official title: Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: adherence
early breast cancer
Arimidex
Therapy adherence
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-03-05
Enrollment: 1077
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Early breast cancer patients on adjuvant aromatase inhibitor

Brief summary: The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.


Eligibility criteria: Inclusion Criteria:

* Early breast cancer
* Post menopausal
* Adjuvant hormonal Arimidex therapy

Primary outcomes:
measure: Percent of patients remaining adherent to therapy with Arimidex
timeFrame: Every 3 months
Secondary outcomes:
measure: Questionnaire for factors influencing adherence
timeFrame: Every 3 months
Other outcomes:
Locations:
city: Balatonfoldvar
country: Hungary
facility: Research Site
city: Bekescsaba
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Debrecen
country: Hungary
facility: Research Site
city: Dombovar
country: Hungary
facility: Research Site
city: Gyongyos
country: Hungary
facility: Research Site
city: Gyor
country: Hungary
facility: Research Site
city: Gyula
country: Hungary
facility: Research Site
city: Kaposvar
country: Hungary
facility: Research Site
city: Kecskemet
country: Hungary
facility: Research Site
city: Miskolc
country: Hungary
facility: Research Site
city: Mosdos
country: Hungary
facility: Research Site
city: Nagyatad
country: Hungary
facility: Research Site
city: Nyiregyhaza
country: Hungary
facility: Research Site
city: Orfu
country: Hungary
facility: Research Site
city: Papa
country: Hungary
facility: Research Site
city: Pecs
country: Hungary
facility: Research Site
city: Szeged
country: Hungary
facility: Research Site
city: Szekesfehervar
country: Hungary
facility: Research Site
city: Szekszard
country: Hungary
facility: Research Site
city: Szentes
country: Hungary
facility: Research Site
city: Szombathely
country: Hungary
facility: Research Site
city: Veszprem
country: Hungary
facility: Research Site
city: Zalaegerszeg
country: Hungary
facility: Research Site
city: Zirc
country: Hungary
facility: Research Site
Study officials:
affiliation: Hungarian National Institute of Oncology
name: Zsolt Horvath, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02988609: Concussion in Rugby Players: a Pilot Study of Neural Recovery Using fMRI
Official title: Concussion in Rugby Players: a Pilot Study of Neural Recovery Using Functional Magnetic Resonance Imaging (fMRI)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Concussion
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2016-12-09
Enrollment: 44
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study assess the putative persistence of neural damage using resting state fMRI after concussion in rugby player once they have clinically recovered. The hypothesis is that despite a clinical recovery (absence of symptoms; neurological and neuropsychological examination returned to normal) connectivity map obtained using resting state fMRI are significantly different from a group of control subjects.

Detailed description: Resting state fMRI has shown to be a sensitive tool to assess neural damage after concussion. It seems more sensible than structural MRI including DTI. the study goal will be to assess rugby players using fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3). The study would specifically like to challenge clinical examination supposed to be normal at V2 to connectivity maps using resting state fMRI preformed at the same time. fMRI performed at V1 and V3 will serve as comparators (respectively very altered at V1 and back to normal at V3).

Eligibility criteria: Inclusion Criteria:

* no neurological or psychiatric disease
* recent history of concussion (\<3 months) according to the Rugby French Federation criteria.

Exclusion Criteria:

* Inability to be assessed by MRI

Primary outcomes:
measure: Difference of connectivity maps between the players with concussion and the group control
timeFrame: up to 1 month
Secondary outcomes:
measure: Difference of connectivity maps between the players with concussion and the group control
timeFrame: up to 3 months
measure: neuropsychological questionnaire
timeFrame: up to 3 months
measure: neurophysiological data
timeFrame: up to 3 months
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Hospital
Study officials:
affiliation: U H Toulouse
name: David BRAUGE, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Smits M, Houston GC, Dippel DW, Wielopolski PA, Vernooij MW, Koudstaal PJ, Hunink MG, van der Lugt A. Microstructural brain injury in post-concussion syndrome after minor head injury. Neuroradiology. 2011 Aug;53(8):553-63. doi: 10.1007/s00234-010-0774-6. Epub 2010 Oct 6.